MTRNR2L13

Across TCGA pan-cancer cohorts, MTRNR2L13 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated MTRNR2L13 data layer compared with 2 for mutation status.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MTRNR2L13 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTRNR2L13 expression acts as an unfavorable survival marker, although some lineages such as LIHC and PAAD show a favorable association.

CHOL, UCEC, and LIHC are the cancer types where MTRNR2L13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.089	0.718	<.001	90	view →
UCEC	DFS	Tertile	II,III,IV	0.726	0.855	.005	60	view →
LIHC	OS	Tertile	III,IV	0.820	0.544	.001	47	view →
UCS	DFS	Tertile	IV	0.132	0.718	.002	42	view →
PAAD	OS	Tertile	All	0.733	0.442	.003	39	view →
READ	DFS	Tertile	IV	0.251	0.682	.004	28	view →
THYM	DFS	Tertile	II,III,IV	0.664	0.926	.004	27	view →
THCA	OS	Quartile	II,III,IV	0.942	1.000	<.001	21	view →
LUSC	OS	Tertile	IV	0.001	0.651	.025	18	view →
LUAD	DFS	Tertile	III,IV	0.713	0.400	.012	18	view →
MESO	OS	Tertile	IV	0.269	0.639	.027	15	view →
DLBC	DFS	Tertile	IV	0.120	0.827	.025	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

MTRNR2L13–CHOL (OS)

Open the CHOL breakdown →